Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11871911 | 1.00 | RAB9A (0.46) | RAB9ATP53HDAC4HDAC2HDAC8 | |
| Hydrochloric Acid SCHEMBL11870858 | 1.00 | RAB9A (0.46) | RAB9ATP53HDAC4HDAC2HDAC8 | |
| SCHEMBL11879078 | 0.98 | RAB9A (0.44) | RAB9ATP53HDAC4HDAC2HDAC8 | |
| SCHEMBL9102041 | 0.98 | RAB9A (0.44) | RAB9ATP53HDAC4HDAC2HDAC8 | |
| SCHEMBL3702604 | 0.94 | TP53 (0.47) | RAB9ATP53HDAC4HDAC2HDAC8 | |
| SCHEMBL28330036 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL11871905 | 0.85 | HDAC4 (0.38) | RAB9ATP53HDAC4HDAC2HDAC8 | |
| SCHEMBL11874913 | 0.83 | HDAC4 (0.39) | RAB9AHDAC4HDAC2HDAC8HDAC6 | |
| SCHEMBL11870851 | 0.83 | HDAC4 (0.39) | RAB9AHDAC4HDAC2HDAC8HDAC6 | |
| SCHEMBL11871053 | 0.81 | HDAC4 (0.38) | RAB9AHDAC4HDAC2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034042-A1 | Composition with Improved SPF and UVA Photoprotection | SYMRISE AG (DE) | 2026-02-05 | — | — | US | claimed |
| US-8877738-B2 | Antipathogenic peptides | SPIDERBIOTECH S.R.L. (IT) | 2014-11-04 | — | — | US | claimed |
| EP-2462155-A1 | NOVEL ANTIPATHOGENIC PEPTIDES | Spiderbiotech S.r.l. (IT) | 2012-06-13 | — | — | EP | claimed |
| US-20120121623-A1 | NOVEL ANTIPATHOGENIC PEPTIDES | SPIDERBIOTCH S.r.L. (IT) | 2012-05-17 | — | — | US | claimed |
| WO-2011015628-A1 | NOVEL ANTIPATHOGENIC PEPTIDES | SPIDERBIOTECH S.R.L. (IT) | 2011-02-10 | — | — | WO | claimed |
| EP-2462155-B1 | NOVEL ANTIPATHOGENIC PEPTIDES | SPIDERBIOTECH SRL (IT) | 2015-05-27 | — | — | EP | disclosed |
| US-8877738-B2 | Antipathogenic peptides | SPIDERBIOTECH S.R.L. (IT) | 2014-11-04 | — | — | US | disclosed |
| EP-2462155-A1 | NOVEL ANTIPATHOGENIC PEPTIDES | Spiderbiotech S.r.l. (IT) | 2012-06-13 | — | — | EP | disclosed |
| US-20120121623-A1 | NOVEL ANTIPATHOGENIC PEPTIDES | SPIDERBIOTCH S.r.L. (IT) | 2012-05-17 | — | — | US | disclosed |
| WO-2011015628-A1 | NOVEL ANTIPATHOGENIC PEPTIDES | SPIDERBIOTECH S.R.L. (IT) | 2011-02-10 | — | — | WO | disclosed |
| US-6756500-B1 | SUBJECTING SUBSTITUTED ALPHA, OMEGA-DIENE IN PRESENCE OF RUTHENIUM, OSMIUM OR MOLYBDENUM HOMOGENEOUS OR HETEROGENEOUS CATALYST TO METATHESIS REACTION IN PRESENCE OF IONIC LIQUID TO FORM CYCLIC COMPOUND | BAYER AKTIENGESELLSCHAFT (DE) | 2004-06-29 | — | — | US | disclosed |
| EP-0990641-B1 | Process for the synthesis of alpha-substituted ring systems | BAYER CHEMICALS AG (DE) | 2004-03-17 | — | — | EP | disclosed |
| WO-2004020650-A2 | AN ENZYMATIC PROCESS FOR PREPARING BETA-LACTAMS | BIOFERMA MURCIA, S.A. (ES) | 2004-03-11 | — | — | WO | disclosed |
| WO-2004020651-A1 | AN ENZYMATIC PROCESS FOR PREPARING BETA-LACTAMS | BIOFERMA MURCIA, S.A. (ES) | 2004-03-11 | — | — | WO | disclosed |
| EP-1394262-A1 | An enzymatic process for preparing beta-lactams | Bioferma Murcia, S.A. (ES) | 2004-03-03 | — | — | EP | disclosed |
| EP-1035093-B1 | Metathesis in the presence of ionic liquids | BAYER AG (DE) | 2003-09-10 | — | — | EP | disclosed |
| US-6235925-B1 | RING CLOSURE METHATHESIS AND NOBLE METAL CATALYSTS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-05-22 | — | — | US | disclosed |
| EP-1035093-A2 | Metathesis in the presence of ionic liquids | BAYER AG (DE) | 2000-09-13 | — | — | EP | disclosed |
| EP-0990641-A1 | Process for the synthesis of alpha-substituted ring systems | Bayer Aktiengesellschaft (DE) | 2000-04-05 | — | — | EP | disclosed |
| US-3937699-A | BACTERICIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1976-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121623-A1 | NOVEL ANTIPATHOGENIC PEPTIDES | MAVS, VIP, ZC3HAV1 | RAB9A 3088/4885TP53 838/4885HDAC4 3927/4885 |
| US-20260034042-A1 | Composition with Improved SPF and UVA Photoprotection | TYR, ERG28, CUTA | RAB9A 1541/4885TP53 165/4885HDAC4 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.